KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Current Taxes (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Current Taxes data on record, last reported at $875.0 million in Q1 2025.

  • For Q1 2025, Current Taxes rose 17.99% year-over-year to $875.0 million; the TTM value through Mar 2025 reached $875.0 million, up 17.99%, while the annual FY2025 figure was $876.4 million, 15.0% up from the prior year.
  • Current Taxes reached $875.0 million in Q1 2025 per TAK's latest filing, up from $741.6 million in the prior quarter.
  • Across five years, Current Taxes topped out at $1.8 billion in Q1 2023 and bottomed at $741.6 million in Q1 2024.
  • Average Current Taxes over 5 years is $1.3 billion, with a median of $1.4 billion recorded in 2021.
  • Peak YoY movement for Current Taxes: rose 26.03% in 2022, then plummeted 57.78% in 2024.
  • A 5-year view of Current Taxes shows it stood at $1.4 billion in 2021, then grew by 26.03% to $1.7 billion in 2022, then grew by 1.61% to $1.8 billion in 2023, then tumbled by 57.78% to $741.6 million in 2024, then grew by 17.99% to $875.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $875.0 million in Q1 2025, $741.6 million in Q1 2024, and $1.8 billion in Q1 2023.